Discover our Biotech Specialist SEIS Fund, focused on early-stage UK biotech companies in drug discovery and AI technologies, and explore our diverse portfolio.
Introduction
The biotechnology sector is at the forefront of innovation, driving advancements in healthcare, drug discovery, and cutting-edge AI technologies. For investors looking to make a meaningful impact while benefiting from attractive tax incentives, investing in biotech startups offers a compelling opportunity. Our Seed Enterprise Investment Scheme (SEIS) Specialist Fund is meticulously designed to support early-stage UK biotech companies, providing both growth potential and financial advantages for investors.
Why Invest in Biotechnology?
Biotechnology is a rapidly evolving field with the potential to revolutionize medical treatments and improve quality of life. Key areas of focus include:
- Novel Drug Discovery: Developing new medications to treat cancer, depression, and other critical diseases.
- AI Technologies: Leveraging artificial intelligence to enhance research and development processes.
- Enabling Services: Providing essential tools and services that support biotech research and commercialization.
Investing in biotech startups not only fosters innovation but also positions investors at the cutting edge of scientific breakthroughs.
Understanding SEIS: A Tax-Efficient Investment
The Seed Enterprise Investment Scheme (SEIS) is a UK government initiative designed to encourage investment in early-stage companies by offering significant tax reliefs. Key benefits include:
- Income Tax Relief: Investors can claim up to 50% tax relief on investments up to £100,000 per tax year.
- Capital Gains Tax (CGT) Exemption: Any gains on SEIS shares are exempt from CGT if the shares are held for at least three years.
- Loss Relief: In the unfortunate event that the investment fails, investors can offset losses against their income tax.
These incentives make SEIS an attractive option for those investing in biotech startups, reducing the financial risk while maximizing potential returns.
Our SEIS Specialist Fund
Our SEIS Specialist Fund focuses on early-stage UK biotech companies, particularly those engaged in novel drug discovery and AI technologies. Here’s what sets our fund apart:
Diverse Portfolio
Our portfolio includes a variety of innovative biotech companies, covering areas such as:
- Cancer Research: Developing personalized medicines to treat heterogeneous cancers.
- Infectious Diseases: Creating advanced therapies to combat infectious diseases.
- Anti-Aging: Researching treatments to slow down the aging process.
Experienced Team
With over 20 years of active experience in biotech investing, our team brings unparalleled knowledge and expertise to the table. We conduct thorough due diligence to ensure that each investment is sound and has the potential for significant growth.
Tax-Efficient Growth
Investors benefit from multiple SEIS tax reliefs, making our fund a highly tax-efficient investment tool. With a target IRR of 20%, our fund aims to deliver substantial capital growth while minimizing tax liabilities.
Commitment to Innovation
Approximately 50% of our portfolio consists of first-time investments, with around 40% being university spinouts. This commitment to nurturing groundbreaking research from inception ensures that our fund remains at the forefront of biotech innovation.
Portfolio Highlights
Our current portfolio showcases the diversity and potential of biotech startups within our SEIS fund:
- Enedra Therapeutics Ltd: Pioneering personalized medicines for treating heterogeneous cancers.
- Sansanima Ltd: Developing in vitro, cell-based assay technologies to replace animal testing.
- Atelerix Ltd: Creating hypothermic gel-based technology to preserve live cells, tissues, and viruses at room temperature.
These companies represent just a snapshot of our diverse and impactful investments.
Why Choose Our SEIS Fund?
Investing with us offers numerous advantages:
- Commission-Free Funding: We eliminate commission fees, ensuring more of your investment goes directly into supporting innovative biotech startups.
- Curated Opportunities: Our focused approach on SEIS-funded biotech companies guarantees high-potential investment opportunities.
- Educational Resources: We provide comprehensive educational tools to help investors make informed decisions about SEIS/EIS investments.
Recent Successes
Our commitment to excellence has been recognized in the industry:
- EISA Impact Awards 2025: Recognized for Exonate’s Topical Eye-Drop for Diabetic Retinopathy.
- Two EISA Awards Shortlist: Awarded for Impact and Ecosystem Champion.
- SEIS Investment in Sansanima: Supporting a University of Sheffield spinout developing alternatives to animal testing.
Get Started Today
Investing in biotech startups through our SEIS Specialist Fund not only supports groundbreaking research but also offers substantial tax benefits and growth potential. Join us in revolutionizing the UK’s biotechnology landscape.
